亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Treatment Toxicity in Elderly Patients With Advanced Non–Small Cell Lung Cancer

医学 毒性 优势比 内科学 化疗 中性粒细胞减少症 置信区间 肺癌 阶段(地层学) 外科 古生物学 生物
作者
Minal Kale,Grace Mhango,Jorge Gómez,Keith Sigel,Cardinale B. Smith,Marcelo Bonomi,Juan P. Wisnivesky
出处
期刊:American Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (5): 470-476 被引量:21
标识
DOI:10.1097/coc.0000000000000188
摘要

Objectives: Toxicity is a main concern limiting the use of chemotherapy and radiotherapy (RT) for elderly patients with non–small cell lung cancer (NSCLC). The objective of this study was to assess the rates of treatment-related toxicity among elderly stage IIIB and IV NSCLC patients. Materials and Methods: We used the Surveillance, Epidemiology, and End Results registry linked to Medicare records to identify 2596 stage IIIB and 14,803 stage IV NSCLC patients aged 70 years and above, diagnosed in 2000 or later. We compared rates of toxicity requiring hospitalization according to treatment (chemotherapy, RT, or chemoradiation [CRT]) in unadjusted and adjusted models controlling for selection bias using propensity scores. Results: Among stage IIIB patients, rates of any severe toxicity were 10.1%, 23.8%, 30.4%, and 39.2% for patients who received no treatment, RT, chemotherapy alone, and CRT, respectively. In stage IV patients, rates of any severe toxicity were 31.5% versus 13.5% among those treated with and without chemotherapy, respectively. In stage IIIB patients treated with CRT, the most common toxicities was esophagitis (odds ratio, 48.5; 95% confidence interval, 6.7-350.5). Among stage IV patients treated with chemotherapy, the risk of toxicity was highest for neutropenia (odds ratio, 8.4; 95% confidence interval, 6.1-11.5). Conclusions: Toxicity was relatively common among stage IIIB patients with up to a 6-fold increase in elderly individuals treated with CRT and a 4-fold increase in toxicities among stage IV patients. This information should be helpful to guide discussions about the risk-benefit ratio of chemotherapy and RT in elderly patients with advanced NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
威武的雨筠完成签到 ,获得积分10
9秒前
研友_VZG7GZ应助哈哈哈哈采纳,获得10
12秒前
momochichu发布了新的文献求助10
13秒前
15秒前
15秒前
19秒前
Wakakak发布了新的文献求助10
20秒前
高贵逍遥完成签到 ,获得积分10
20秒前
wyz完成签到 ,获得积分10
21秒前
23秒前
冰激凌完成签到,获得积分10
24秒前
24秒前
Yu发布了新的文献求助10
26秒前
小乘号子发布了新的文献求助30
26秒前
。。完成签到,获得积分10
27秒前
量子星尘发布了新的文献求助10
29秒前
哈哈哈哈发布了新的文献求助10
30秒前
故意的山河完成签到,获得积分10
32秒前
Linda发布了新的文献求助10
34秒前
struggling2026完成签到 ,获得积分10
39秒前
科研通AI5应助Wakakak采纳,获得10
40秒前
喂喂发布了新的文献求助20
42秒前
lena完成签到 ,获得积分10
48秒前
情怀应助小乘号子采纳,获得10
49秒前
50秒前
深情安青应助深情访文采纳,获得10
55秒前
星辰大海应助科研通管家采纳,获得10
58秒前
wanci应助科研通管家采纳,获得10
58秒前
共享精神应助科研通管家采纳,获得10
58秒前
大模型应助科研通管家采纳,获得30
58秒前
58秒前
半城微凉应助科研通管家采纳,获得10
58秒前
万能图书馆应助Linda采纳,获得10
1分钟前
咸鱼lmye完成签到 ,获得积分20
1分钟前
爆米花应助Djnsbj采纳,获得10
1分钟前
1分钟前
echo完成签到,获得积分10
1分钟前
1分钟前
慕青应助橘猫217采纳,获得10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204482
捐赠科研通 3257320
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613